To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients

Critical Reviews in Oncology/Hematology

Volumn 97, Issue , 2016, Pages 247-262

  Hall, Alix E ^a   Paul, Chris ^a   Bryant, Jamie ^a   Lynagh, Marita C ^a   Rowlings, Philip ^b,c   Enjeti, Anoop ^b,c   Small, Hannah ^a  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Adherence; Compliance; Hemato oncology; Hematological cancer; Medication

Indexed keywords

ASPARAGINASE; ASPARAGINASE 1; BOSUTINIB; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CANCER SURVIVOR; CHRONIC MYELOID LEUKEMIA; DATA CODING; DATA EXTRACTION; DRUG SELF ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC MALIGNANCY; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PUBLICATION; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT REFUSAL; HEMATOLOGIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MEDICATION ADHERENCE;

EID: 84952639455     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.08.025     Document Type: Review

References (82)

1. Australian Institute of Healthand Welfare & Australasian Association of Cancer Registries Cancer in Australia: an overview, 2012. Cancer series no. 74. Cat. no. CAN 70 2012, AIHW, Canberra.
2. Abraham L., et al. Nonadherence with imatinib treatment in chronic myeloid leukemia is a function of disease, health, knowledge and social factors - results from the ADAGIO study. Haematologica 2008, 93:233.
3. Agrawal M., et al. Tyrosine kinase inhibitors: the first decade. Curr. Hematol. Malig. Rep. 2010, 5(2):70-80.
4. Almeida M., et al. High adherence to tyrosine kinase inhibitors seems to be related to best cytogenetic response in the hasford lower risk group in Chronic Myeloid Leukemia. Blood 2010, 116(21).
5. Barley E.A., et al. Managing depression in primary care: A meta-synthesis of qualitative and quantitative research from the UK to identify barriers and facilitators. BMC Fam. Pract. 2011, 12(1):47.
6. Bazeos A., et al. Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. ASH Annual Meeting 2009, 3290. Abstract.
7. Bhatia S., et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J. Clin. Oncol. 2012, 30:2094-2101. 10.1200/JCO.2011.38.9924.
8. Bhatia S., et al. Nonadherence to oral 6-mercaptopurine (6MP) in a multi-ethnic cohort of children with acute lymphoblastic leukemia (ALL) and its impact on relapse-a children's oncology group (COG) study (AALL03N1). Blood 2012, 120(21):612. Abstract.
9. Blasdel C., Bubalo J. Adherence to oral cancer therapies: meeting the challenges of new patient care needs. Oncology 2006, 1-4. Special Report 09:06 (April 2006).
10. Breccia M., Efficace F., Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far?. Cancer Lett. 2011, 300(2):115-121.
11. CASP. Critical Appraisal Skills Programme: 10 questions to help you make sense of qualitative research. 2013 [cited 2014 August]; Available from:. http://www.caspinternational.org/mod_product/uploads/CASP%20Qualitative%20Research%20Checklist%2031.05.13.pdf.
12. Casamartina E.F., et al. Study of variability in the response to imatinib treatment in Chronic Myeloid Leukemia Ph+ patients. J. Oncol. Pharm. Pract. 2010, 16(Suppl. 1):9.
13. Christiansen N., Taylor K.M., Duggan C. Oral chemotherapy in paediatric oncology in the UK: problems, perceptions and information needs of parents. Pharmacy World & Science 2008, 30(5):550-555.
14. Cortes J.E., et al. uality of life during early tyrosine kinase inhibitor treatment as self-reported by chronic myeloid leukemia patients participating in a prospective observational study (simplicity). Blood (ASH Annual Meeting Abstracts) 2011, 118:4435. Abstract.
15. Darkow T., et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs. Pharmacoeconomics 2007, 25(6):481-496.
16. De Almeida M., et al. Adherence to tyro-sine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) seems to be related to duration of treatment and type of TKI. Haematologica 2010, 95(Suppl. 2).
17. DiMatteo M.R., et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med. Care 2002, 40(9):794-811.
18. DiMatteo M.R., Haskard K.B., Williams S.L. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med. Care 2007, 45(6):521-528.
19. DiMatteo M.R. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004, 23(2):207.
20. Doti C., et al. Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study. Blood 2007, 11:4553.
21. Doti C.A., et al. Adherence to imatinib mesylate treatment: two years follow up blood. Abstract 2008, 112(11):4267.
22. Efficace F., et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br. J. Cancer 2012, 107(6):904-909.
23. Eliasson L., et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk. Res. 2011, 35(5):626-630.
24. Farley J., et al. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J. Acquir. Immune Defic. Syndr. 2003, 2:211-218.
25. Feng W., et al. Compliance and persistency with imatinib. J. Clin. Oncol. (ASCO Annual Meeting) 2006, 24(18S):6038. Abstract.
26. Ganesan P., et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am. J. Hematol. 2011, 86(6):471-474.
27. Gater A., et al. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk. Res. 2012, 36(7):817-825.
28. Guérin A., et al. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr. Med. Res. Opin. 2012, 28(7):1155-1162.
29. Guerin A., et al. Non-adherence to imatinib in chronic myeloid leukemia (cml) patients is associated with short- and long-term negative impacts on health care resource utilization and costs. Value Health 2010, 13(3):A32.
30. Guerin A., et al. Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia. ASH Annu. Meeting Abstr. 2011, 2754. December 2011, Abstract.
31. Guilhot F., et al. A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML). Blood 2010, 116(21):1514. Abstract.
32. Guilhot F., et al. An enthnographic investigation tracking the experience of chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapies. Blood 2010, 116(21):394. Abstract.
33. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit. Rev. Oncol. Hematol. 2010, 73(3):156-166.
34. Halpern R., Barghout V., Williams D. Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST. Blood (ASH Annual Meeting Abstracts) 2007, 110:5159. Abstract.
35. Haynes R.B., McDonald H.P., Garg A.X. Helping patients follow prescribed treatment: clinical applications. JAMA 2002, 288(22):2880-2883.
36. Haynes R.B., et al. Interventions for enhancing medication adherence. Cochrane Database Syst. Rev. 2008, 2.
37. Hohneker J., Shah-Mehta S., Brandt P.S. Perspectives on adherence and persistence with oral medications for cancer treatment. J. Oncol. Pract. 2011, 7(1):65-67.
38. Ibrahim A.R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term imatinib therapy. Blood (ASH Annual Meeting Abstracts) 2010, 116:3414. Abstract.
39. Ibrahim A.R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011, 117(14):3733-3736.
40. Jönsson S., et al. Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study. Ann. Hematol. 2012, 91(5):679-685.
41. Jabbour E.J., et al. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am. J. Hematol. 2012, 87(7):687-691.
42. Jacobsen P., et al. Adherence to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). Blood 2011, 4431. Abstract.
43. Jaime-Perez J.C., et al. Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia. Leuk. Lymphoma 2009, 50(11):1843-1847.
44. Johnson C.N., et al. Disease knowledge in chronic myeloid leukemia (CML) patients as a predictor of compliance to treatment. Blood (ASH Annual Meeting Abstracts) 2010, 116:4481. Abstract.
45. Kishore B., Marin D. Current opinions and controversies in chronic myeloid leukaemia. Curr. Opin. Oncol. 2011, 23(6):659-664.
46. Koren-Michowitz M., et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol. Oncol. 2012, 30(4):200-205.
47. Landier W., et al. A grounded theory of the process of adherence to oral chemotherapy in Hispanic and caucasian children and adolescents with acute lymphoblastic leukemia. J. Pediatr. Oncol. Nurs. 2011, 4:203-223.
48. Landier W. Adherence to oral chemotherapy in childhood acute lymphoblastic leukemia: an evolutionary concept analysis. Oncol. Nurs. Forum 2011, 38(3):343-352.
49. Larizza M., et al. Factors influencing adherence to molecular therapies in haematology- outpatients. J. Pharm. Pract. Res. 2006, 36(2):115-118.
50. Lee S., et al. Imatinib meslylate plasma levels predict compliance in patients with chronic myelogenous leukemia. Blood 2009, 114(22).
51. Liberati A., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. BMJ 2009, 339. b2700.
52. Malbasa T., Kodish E., Santacroce S.J. Adolescent adherence to oral therapy for leukemia: a focus group study. J. Pediatr. Oncol. Nurs. 2007, 24(3):139-151.
53. Mancini J., et al. Adherence to leukemia maintenance therapy: a comparative study among children, adolescents, and adults. Pediatr. Hematol. Oncol. 2012, 29(5):428-439.
54. Marin D., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 2010, 28(14):2381-2388.
55. Marin D., et al. Adherence to imatinib therapy is the critical factor for achieving molecular responses in patients with chronic myeloid leukaemia. Br. J. Haematol. 2010, 149(Suppl. 1):81.
56. Maroun J.A., et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003, 21(14):1039-1051.
57. NICE Guidance on Cancer Services Improving Outcomes in Haematological Cancers: The Manual 2003, National Institute for Clinical Excellence, London.
58. Noens L., et al. Patient nonadherence and treatment response to imatinib in patients with chronic myeloid leukemia: results from the ADAGIO study. Blood (ASH Annual Meeting Abstracts) 2008, 112:2379. Abstracts.
59. Noens L., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411.
60. Noens L., et al. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 2014, 99(3):437-447.
61. Oliveira B.M.D., et al. Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia. Arch. Dis. Child. 2004, 89(8):785-788.
62. Oliveira B.M.D., et al. Evaluation of compliance through specific interviews: a prospective study of 73 children with acute lymphoblastic leukemia. J. Pediatr. 2005, 81(3):245-250.
63. Oliveria S.A., et al. Treatment adherence in patients with chronic myeloid leukemia in a real world setting. Blood 2011, 4424. Abstract.
64. Optum. What we do: improve quality by measuring patient outcomes. 2014 [cited 2014 December 8th]; Available from:. http://https://www.optum.com/optum-outcomes/what-we-do.html.
65. Osterberg L., Blaschke T. Adherence to medication. N. Engl. J. Med. 2005, 353(5):487-497.
66. Oyekan E., et al. The B-SMART appropriate medication-use process: a guide for clinicians to help patients-Part 2: adherence, relationships, and triage. Permanente J. 2009, 13(4):50.
67. Oyekan E.et al. The B-SMART appropriate medication-use process: a guide for clinicians to help patients-Part 1: barriers, solutions, and motivation. Permanente J. 2009, 13(1):62.
68. Pai A.L., Drotar D., Kodish E. Correspondence between objective and subjective reports of adherence among adolescents with acute lymphoblastic leukemia. Child. Health Care 2008, 37(3):225-235.
69. Puts M.T.E., et al. Factors influenncing adherence to cancer treatment in older adults with cancer: a systematic review. Ann. Oncol. 2014, 25(3):564-577.
70. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA. Cancer J. Clin. 2009, 59(1):56-66.
71. Sabaté E. Adherence to long-term therapies: evidence for action. World Health Organization. 2003.
72. Sitaresmi M.N., et al. Chemotherapy-related side effects in childhood acute lymphoblastic leukemia in Indonesia: parental perceptions. J. Pediatr. Oncol. Nurs. 2009, 26(4):198-207.
73. StCharles M., et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2009, 114(22). Abstract.
74. Van Lierde M.-A., et al. Canonical correlation analysis (CCA) of imatinib treatment (ImRx) nonadherence (NA) with associated patient variables (APVs) in chronic myeloid leukemia (CML)-results from the ADAGIO study. Blood (ASH Annual Meeting Abstracts) 2007, 110:5164. Abstract.
75. Van Lierde M.-A., et al. Multimethod clinical assessment of patterns and prevalence of nonadherence (NA) to imatinib treatment (IMRx) in patients (Pts) with chronic myeloid leukemia (CML): results from the ADAGIO study. Blood (ASH Annual Meeting Abstracts) 2007, 110:5163. Abstract.
76. Weingart S., et al. NCCN Task Force Report: oral chemotherapy. J. National Compr. Cancer Netw.: JNCCN 2008, 6:S1-14.
77. Wu E.Q., et al. Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs. Blood (ASH Annual Meeting Abstracts) 2009, 114:4270. Abstract.
78. Wu E.Q., et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr. Med. Res. Opin. 2010, 26(1):61-69.
79. Wu E.Q., et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr. Med. Res. Opin. 2010, 26(12):2861-2869.
80. Wu S., et al. What doctors don't know about adherence: a qualitative study of adherence to imatinib amongst patients with chronic myeloid. Leukaemia Psychooncology 2011, 20(Suppl. 2):P1-127.
81. Yood M.U., et al. Adherence to treatment in patients with chronic myelogenous leukemia during a 10-year time period: a medical record review. Blood (ASH Annual Meeting Abstracts) 2010, 115:1235. Abstract.
82. Yood M.U., et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr. Med. Res. Opin. 2012, 28(2):213-219.